Vaccines for both pandemic and seasonal influenza, as well as other infectious diseases, based on proprietary Toll-like Receptor (TLR) technology platform. Clinical stage.
Cranbury, NJ
Total raised: $6.597M
Investors 1
| Date | Name | Website |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 03.10.2014 | - | $6M | - | medcitynew... |
| 26.07.2007 | Grant | $597K | - | venturebea... |
Mentions in press and media 8
| Date | Title | Description | Category | Author | Source |
| 29.09.2015 | VaxInnate ... | The company launched a Phase 2... | - | - | medcitynew... |
| 03.10.2014 | Well-capit... | Vaxinnate claims it’s got the ... | - | - | medcitynew... |
| 02.04.2012 | Former hea... | Last year, it was granted a fi... | - | - | medcitynew... |
| 26.07.2007 | VaxInnate ... | VaxInnate, a Cranbury, N.J., v... | - | - | venturebea... |
| 25.10.2006 | Vaccine co... | VaxInnate, of Cranbury, NJ sai... | - | - | venturebea... |
| - | VaxInnate ... | New Jersey startup VaxInnate k... | - | - | medcitynew... |
| - | Former hea... | The former head of Sanofi’s (N... | - | - | medcitynew... |
| - | Well-capit... | New Jersey’s VaxInnate is deve... | - | - | medcitynew... |